BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9329572)

  • 1. Significance of tumor marker determinations in the primary therapy of ovarian cancer.
    Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2949-51. PubMed ID: 9329572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
    Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
    Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
    Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
    Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CA-125 antigen].
    Zakrzewska I
    Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
    Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
    Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
    Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
    Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
    Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
    Oishi T; Maruo T; Iwasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK; Nørgaard-Pedersen B; Mogensen O
    Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery.
    Meier W; Stieber P; Hasholzner U; Gropp M; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2945-7. PubMed ID: 9329571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
    Porsbjerg CM; Sørensen JB; Lund BA
    Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor marker in ovarian cancer].
    Komai K; Nishida T
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.